

# IFNGR2 Antibody (C-term) Blocking Peptide

Synthetic peptide Catalog # BP6995b

### **Specification**

## IFNGR2 Antibody (C-term) Blocking Peptide - Product Information

Primary Accession

P38484

### IFNGR2 Antibody (C-term) Blocking Peptide - Additional Information

**Gene ID 3460** 

#### **Other Names**

Interferon gamma receptor 2, IFN-gamma receptor 2, IFN-gamma-R2, Interferon gamma receptor accessory factor 1, AF-1, Interferon gamma transducer 1, IFNGR2, IFNGT1

## **Target/Specificity**

The synthetic peptide sequence used to generate the antibody <a href=/products/AP6995b>AP6995b</a> was selected from the C-term region of human IFNGR2. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

#### **Format**

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

#### Storage

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

#### **Precautions**


This product is for research use only. Not for use in diagnostic or therapeutic procedures.

### IFNGR2 Antibody (C-term) Blocking Peptide - Protein Information

#### Name IFNGR2 (HGNC:5440)

# **Function**

Associates with IFNGR1 to form a receptor for the cytokine interferon gamma (IFNG) (PubMed:<a href="http://www.uniprot.org/citations/7615558" target="\_blank">7615558</a>, PubMed:<a href="http://www.uniprot.org/citations/7673114" target="\_blank">7673114</a>, PubMed:<a href="http://www.uniprot.org/citations/8124716" target="\_blank">8124716</a>). Ligand binding stimulates activation of the JAK/STAT signaling pathway (PubMed:<a href="http://www.uniprot.org/citations/15356148" target="\_blank">15356148</a>, PubMed:<a href="http://www.uniprot.org/citations/7673114" target="\_blank">7673114</a>, PubMed:<a href="http://www.uniprot.org/citations/8124716" target="\_blank">8124716</a>). Required for signal transduction in contrast to other receptor subunit responsible for ligand binding (PubMed:<a href="http://www.uniprot.org/citations/7673114" target="\_blank">7673114</a>).





### **Cellular Location**

Cell membrane; Single-pass type I membrane protein. Cytoplasmic vesicle membrane; Single-pass type I membrane protein. Golgi apparatus membrane; Single-pass type I membrane protein. Endoplasmic reticulum membrane; Single-pass type I membrane protein. Cytoplasm. Note=Has low cell surface expression and high cytoplasmic expression in T cells. The bias towards cytoplasmic expression may be due to ligand-independent receptor internalization and recycling.

#### **Tissue Location**

Expressed in T-cells (at protein level).

### IFNGR2 Antibody (C-term) Blocking Peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.

#### • Blocking Peptides

IFNGR2 Antibody (C-term) Blocking Peptide - Images

# IFNGR2 Antibody (C-term) Blocking Peptide - Background

IFNGR2 is the non-ligand-binding beta chain of the gamma interferon receptor. Human interferon-gamma receptor is a heterodimer of IFNGR1 and IFNGR2. Defects in IFNGR2 are a cause of mendelian susceptibility to mycobacterial disease (MSMD), also known as familial disseminated atypical mycobacterial infection.

### IFNGR2 Antibody (C-term) Blocking Peptide - References

Kotenko, S.V., et.al., J. Biol. Chem. 270 (36), 20915-20921 (1995)